March 26, 2012

Not intended for U.S. and UK Media - Treatment of Pulmonary Embolism (PE):

Bayer's Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study

Rivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine
Berlin, Germany, March 26, 2012 - Bayer HealthCare announced today that the
oral anticoagulant Xarelto® (rivaroxaban), used as a single drug intervention,
was as effective and safe as the current dual drug approach of subcutaneous
enoxaparin followed by Vitamin K antagonist (VKA), in treating patients with
acute symptomatic pulmonary embolism (PE) and preventing them from developing a
secondary venous blood clot (known as venous thromboembolism or VTE).
Rivaroxaban demonstrated similar overall bleeding rates, but was associated
with significantly lower rates of major bleeding versus the current standard
regimen. These data were presented today as a late-breaker at the American
College of Cardiology Annual Scientific Sessions, and published in the New
England Journal of Medicine.

The EINSTEIN-PE study compared the oral single-drug approach with rivaroxaban
15 mg twice daily for three weeks followed by 20 mg once daily with the current
standard of care of subcutaneous enoxaparin followed by a VKA in the treatment
of 4,833 patients with acute symptomatic PE for the prevention of recurrent
VTE. Patients received treatment for three, six or 12 months. In the study,
rivaroxaban demonstrated efficacy comparable to that of the current standard
therapy in reducing the primary endpoint of recurrent symptomatic VTE, a
composite of symptomatic deep vein thrombosis (DVT) and non-fatal or fatal PE
[2.1% vs. 1.8%, respectively (p=0.003 for non-inferiority)]. Rivaroxaban also
demonstrated similar safety results compared to current standard of care for
the principal safety outcome measuring a composite of major and non-major
clinically relevant bleeding events [10.3% vs. 11.4% (p=0.23), respectively].
Importantly, rivaroxaban treatment resulted in a significant reduction in major
bleeding events [1.1% vs. 2.2% (p=0.003), respectively] compared to the current
standard therapy.

"The results of the EINSTEIN-PE study convincingly demonstrate that rivaroxaban
offers clinicians a simple, single-drug solution to the initial treatment of PE
and the long-term prevention of recurrent VTE, which is as effective as the
current dual-drug approach and equally well tolerated," said Dr. A.G.G. Turpie,
Professor of Medicine at McMaster University, Hamilton, Canada. "These new
findings are of particular importance given the appalling level of morbidity
and mortality associated with venous thromboembolism in Europe and the U.S. and
the frequency of recurrence".

VTE is the collective term for both DVT and PE. DVT occurs when blood clots
form in one of the large, deep veins in the legs. PE is a serious, clinical
condition that most commonly occurs when part or all of a DVT dislodges and
travels to the lung via the heart, where it can partially or completely block a
branch of the pulmonary artery. When PE occurs with large clots, multiple
clots, or when the patient already has pre-existing heart or lung disease, the
event may be fatal.

"Following the recent EU approval of rivaroxaban in DVT treatment, these
results reinforce the clinical importance of rivaroxaban in treating the even
more dangerous pulmonary blood clots, and preventing their recurrence," said
Dr. Kemal Malik, Member of the Bayer HealthCare Executive Committee and Head of
Global Development. "We are planning to file rivaroxaban for marketing
authorization in this indication during the second quarter of this year."

About the EINSTEIN Program

EINSTEIN-PE is one of three Phase III studies in the global EINSTEIN program
that evaluated the safety and efficacy of rivaroxaban in the treatment of
venous thromboembolism in almost 10,000 patients. This multinational,
randomized, event-driven study with blinded outcome assessment was sponsored by
Bayer HealthCare and Janssen Research & Development, LLC.

The other two trials - EINSTEIN-DVT and EINSTEIN-EXT - have already been
presented at the European Society of Cardiology (ESC) Congress in August 2010
and at the 51st Annual Meeting of the American Society of Hematology (ASH) in
December 2009 respectively. Data from EINSTEIN-DVT and EINSTEIN-EXT were
published together in the New England Journal of Medicine in December 2010 (n
engl j med 363;26). On December 9, 2011, Xarelto® (rivaroxaban) received
European Commission approval for the treatment of DVT and the prevention of
recurrent DVT and PE following an acute DVT in adults.

About Venous and Arterial Thromboembolism (VAT)

Thrombosis is the formation of a blood clot inside a blood vessel, blocking a
vein (venous thrombosis) or artery (arterial thrombosis). Venous and Arterial
Thromboembolism (VAT) is caused when some or all of a clot detaches and is
moved within the blood stream until it obstructs a smaller vessel. This can
result in damage to vital organs, because the tissue beyond the blockage no
longer receives nutrients and oxygen.

VAT is responsible for a number of serious and life threatening conditions:


- Venous Thromboembolism (VTE) occurs when part of a clot formed in a deep
vein, for example in the leg (known as deep vein thrombosis, or DVT), is
carried to the lung, via the heart, preventing the uptake of oxygen. This is
known as a pulmonary embolism (PE), an event which can be rapidly fatal.


- Arterial Thromboembolism (ATE) occurs when oxygenated blood flow from the
heart to another part of the body (via an artery) is interrupted by a blood
clot. If this occurs in a vessel supplying blood to the brain, it can lead to a
stroke, an event that can be severely debilitating or fatal. If it occurs in a
coronary artery, it can lead to acute coronary syndrome (ACS), a complication
of coronary heart disease which includes conditions such as myocardial
infarction (heart attack), and unstable angina.

VAT is responsible for significant morbidity and mortality, and requires active
or preventative treatment to avoid potentially serious or fatal patient
outcomes.

About Rivaroxaban (Xarelto®)

Rivaroxaban is an oral anticoagulant that was discovered in Bayer HealthCare's
Wuppertal laboratories in Germany, and is being jointly developed by Bayer
HealthCare and Janssen Research & Development, LLC. It has a rapid onset of
action with a predictable dose response and high bioavailability, no
requirement for routine coagulation monitoring, and a limited potential for
food and drug interactions.

Rivaroxaban is marketed under the brand name Xarelto® for VTE prevention in
adult patients following elective hip or knee replacement surgery, and it is
the only oral anticoagulant that has consistently demonstrated superior
efficacy over enoxaparin in this indication. Rivaroxaban is approved in more
than 110 countries worldwide and is marketed outside the U.S. by Bayer
HealthCare in this indication. On December 9, 2011, Xarelto® received further
marketing approval in the EU for the prevention of stroke and systemic embolism
in patients with Atrial Fibrillation as well as for the treatment of deep vein
thrombosis (DVT) and the prevention of recurrent DVT and pulmonary embolism
following an acute DVT in adult patients.

In the U.S., where rivaroxaban has been available since July 2011 for VTE
prevention in adult patients following elective hip or knee replacement
surgery, Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company) holds
marketing rights. The Bayer HealthCare sales force is supporting Janssen
Pharmaceuticals, Inc. in designated hospital accounts. On November 4, 2011,
Xarelto® received further marketing approval in the U.S. to reduce the risk of
stroke and systemic embolism in patients with nonvalvular Atrial Fibrillation.

The extensive clinical trial program supporting rivaroxaban makes it the most
studied and widely published oral, direct Factor Xa inhibitor. The studies
involve over 75,000 patients for the prevention and treatment of venous and
arterial thromboembolic (VAT) disorders across a broad range of acute and
chronic conditions, including VTE prevention in adult patients following
elective hip or knee replacement surgery, stroke prevention in patients with
Atrial Fibrillation, VTE treatment and the prevention of recurrent DVT or PE,
and for secondary prevention after an Acute Coronary Syndrome.

To learn more about thrombosis, please visit www.thrombosisadviser.com.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of
Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's
leading, innovative companies in the healthcare and medical products industry
and is based in Leverkusen, Germany. The company combines the global activities
of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals
divisions. Bayer HealthCare's aim is to discover, develop, manufacture and
market products that will improve human and animal health worldwide. Bayer
HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is
represented in more than 100 countries. Find more information at
www.bayerhealthcare.com.

Find more information at www.bayerpharma.com.


Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or
developments.